Published Online
on June 15, 2006

A more recent version of this article appeared on August 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/8/2007    most recent 01.STR.0000229905.25080.01v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zee, R. Y.L. Articles by Ridker, P. M Search for Related Content PubMed PubMed Citation Articles by Zee, R. Y.L. Articles by Ridker, P. M Related Collections Epidemiology Genetics of cardiovascular disease

Submitted on March 31, 2006
Accepted on May 2, 2006

Genetic Variants of Arachidonate 5-Lipoxygenase-Activating Protein, and Risk of Incident Myocardial Infarction and Ischemic Stroke. A Nested Case-Control Approach

Robert Y.L. Zee PhD^*; Suzanne Cheng PhD; Hillary H Hegener BS; Henry A. Erlich PhD; and Paul M Ridker MD

From the Center for Cardiovascular Disease Prevention, the Donald W. Reynolds Center for Cardiovascular Research, the Leducq Center for Molecular and Genetic Epidemiology (R.Y.L.Z., H.H.H., P.M.R.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and the Roche Molecular Systems (S.C., H.A.E.), Alameda, Calif.

^* To whom correspondence should be addressed. E-mail: rzee{at}rics.bwh.harvard.edu.

Background and Purpose--Recent findings have implicated specific gene polymorphisms of arachidonate 5-lipoxygenase-activating protein (ALOX5AP), and 2 at-risk haplotypes (HapA, HapB) in myocardial infarction and stroke. To date, no prospective data are available.

Methods--We evaluated 10 specific Icelandic ALOX5AP gene variants among 600 male participants with incident atherothrombotic events (myocardial infarction [MI] or ischemic stroke) and among 600 age- and smoking-matched male participants, all white, who remained free of reported cardiovascular disease during follow-up within the Physicians’ Health Study cohort.

Results--Overall allele, genotype, and haplotype distributions were similar between cases and controls. Single-marker conditional logistic regression analysis adjusted for potential risk factors found no association with risk of atherothrombotic events. Further investigation using a haplotype-based approach showed similar null findings with MI (HapA: odds ratio [OR]=1.18, 95% CI, 0.76 to 1.85; P=0.46; HapB: odds ratio=0.62, 95% CI, 0.36 to 1.07; P=0.08), and with ischemic stroke (HapA: odds ratio=1.11, 95% CI, 0.65 to 1.89; P=0.71; HapB: odds ratio=0.82, 95% CI, 0.47 to 1.42; P=0.47).

Conclusions--We found no evidence for an association of the specific Icelandic ALOX5P gene variants/at-risk haplotypes tested with risk of incident MI nor ischemic stroke in this prospective, non-Icelandic study.

Key words: ALOX5AP • haplotypes • MI • risk factors • stroke

This article has been cited by other articles:

				S. Vikman, R. M. Brena, P. Armstrong, J. Hartiala, C. B. Stephensen, and H. Allayee Functional analysis of 5-lipoxygenase promoter repeat variants Hum. Mol. Genet., December 1, 2009; 18(23): 4521 - 4529. [Abstract] [Full Text] [PDF]

				Xiang Xie, Y.-T. Ma, Z.-y. Fu, Y.-N. Yang, Xiang Ma, B.-D. Chen, Y.-H. Wang, and Fen Liu Haplotype Analysis of the CYP8A1 Gene Associated With Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 574 - 580. [Abstract] [PDF]

				E. Zintzaras, P. Rodopoulou, and N. Sakellaridis Variants of the Arachidonate 5-Lipoxygenase-Activating Protein (ALOX5AP) Gene and Risk of Stroke: A HuGE Gene-Disease Association Review and Meta-Analysis Am. J. Epidemiol., March 1, 2009; 169(5): 523 - 532. [Abstract] [Full Text] [PDF]

				G. Riccioni, V. Capra, N. D'Orazio, T. Bucciarelli, and L. A. Bazzano Leukotriene modifiers in the treatment of cardiovascular diseases J. Leukoc. Biol., December 1, 2008; 84(6): 1374 - 1378. [Abstract] [Full Text] [PDF]

				H. Allayee, A. Baylin, J. Hartiala, H. Wijesuriya, M. Mehrabian, A. J Lusis, and H. Campos Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction Am. J. Clinical Nutrition, October 1, 2008; 88(4): 934 - 940. [Abstract] [Full Text] [PDF]

				M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF]

				R. Y.L. Zee and P. M Ridker Two Common Gene Variants on Chromosome 9 and Risk of Atherothrombosis Stroke, October 1, 2007; 38(10): e111 - e111. [Full Text] [PDF]

				D. K. Arnett and for the Writing Group Summary of the American Heart Association's Scientific Statement on the Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1682 - 1686. [Full Text] [PDF]

				D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]

				D. T. Miller, P. M. Ridker, P. Libby, and D. J. Kwiatkowski Atherosclerosis: The Path From Genomics to Therapeutics J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1589 - 1599. [Abstract] [Full Text] [PDF]